Oligopeptide-1: complete guide

Oligopeptide-1 is a cosmetic peptide name often confused with sh-oligopeptide-1, a recombinant EGF. This guide sorts out the names, the research and the regulatory status.

Complete guide5 min read

Key takeaway

CosIng describes oligopeptide-1 as “Glycine, oligomer with histidine and lysine.” Its separate sh-oligopeptide-1 entry is recombinant EGF with up to 53 amino acids. A PubMed title and abstract search for “oligopeptide-1” returned 3 records, all about EGF. A 2023 review of 9 clinical trials of sh-oligopeptide-1 judged them without scientific basis.

At a glance

Article typeComplete guide
Regulatory statusCosmetic / topical“Oligopeptide-1 is a cosmetic ingredient, not an FDA-approved drug.” (this article)
ClassSkin & cosmetic
Body systemsSkin & connective tissue
Studies cited2 in this article · 2 across 1 article on Oligopeptide-1
Related productsCopper peptides and melanocortin fragments

Oligopeptide-1 is a cosmetic ingredient name that causes real confusion. The EU database defines it as a short glycine, histidine and lysine peptide. A separate entry, sh-oligopeptide-1, is a lab-made copy of human epidermal growth factor (EGF). This guide sorts out the names, the research and the regulatory status. Sources were checked on November 17, 2026.

Quick answer: Oligopeptide-1 and sh-oligopeptide-1 are two different INCI entries. The first is a short peptide made of glycine, histidine and lysine. The second is recombinant human EGF. Both are listed for skin conditioning. Neither is an FDA-approved drug, and we found no Cosmetic Ingredient Review safety assessment for either name.

Vitrapep does not sell oligopeptide-1; this page is a reference summary of published research and regulatory information.

What is oligopeptide-1?

Oligopeptide-1 is an INCI name, the standard name used on cosmetic ingredient lists. “Oligo” means a few, so an oligopeptide is a short chain of amino acids. CosIng, the European Commission’s cosmetic ingredient database, describes oligopeptide-1 as “Glycine, oligomer with histidine and lysine” (CosIng, 2026). It gives no exact sequence.

PubChem files the name Oligopeptide-1 among the synonyms of glycyl-L-histidyl-L-lysine acetate, or GHK acetate. That record lists the formula C16H28N6O6 and a molecular weight of 400.43 g/mol for the acetate salt (PubChem CID 22214678). The same record also lists Tripeptide-1 acetate. For the copper-bound form of GHK, see our GHK-Cu guide.

A separate INCI entry, sh-oligopeptide-1, is something else. CosIng describes it as “a single chain recombinant human peptide, produced by fermentation in E. coli.” Its gene is made “identical to the human gene which codes for Epidermal Growth Factor.” It contains “a maximum of 53 amino acids” (CosIng, 2026). Our peptide vs protein guide explains where a chain that long sits.

Table 1

Oligopeptide-1: key facts

Fact Detail
INCI name Oligopeptide-1 (separate entry: sh-Oligopeptide-1)
Structure type Short synthetic peptide; CosIng: “Glycine, oligomer with histidine and lysine”
Sequence or composition Not given by CosIng; PubChem files the name under Gly-His-Lys acetate
Molecular formula C16H28N6O6 (PubChem Gly-His-Lys acetate record)
Molecular weight 400.43 g/mol (acetate salt, same record)
Main cosmetic function (CosIng) Skin conditioning (sh-oligopeptide-1 also skin conditioning)
Trade name(s) None confirmed from a manufacturer source

How does oligopeptide-1 work?

We found no peer-reviewed study of mechanism under the INCI name oligopeptide-1 as CosIng defines it. Research that uses the name is about EGF instead.

For sh-oligopeptide-1, the design idea is to copy human EGF, a growth factor. A 2023 review tested that idea against the literature. It found that trials treated sh-oligopeptide-1 as if it were a functional recombinant human EGF. It also found that sh-oligopeptide-1 has not been shown to be a functional EGF (Martínez-Carpio, 2023).

In short, the mechanism for either ingredient is not established in the sources we checked.

What is oligopeptide-1 used for?

CosIng lists one cosmetic function for oligopeptide-1: skin conditioning. It lists the same function for sh-oligopeptide-1. A skin-conditioning agent helps keep skin in good condition. Neither CosIng record links an annex of the EU Cosmetics Regulation or a scientific committee opinion.

The name is not used consistently in research. In a 2026 trial, authors described their recombinant EGF serum as containing oligopeptide-1 (Abud et al., 2026). Under CosIng, recombinant EGF belongs under sh-oligopeptide-1. For other cosmetic peptides, see our peptides in skincare overview.

What does the research show?

Literature size. A PubMed search for “oligopeptide-1” in titles and abstracts returned three records on November 17, 2026. All three concern EGF, not the CosIng glycine, histidine and lysine peptide.

Martínez-Carpio 2023 (review). A March 2023 literature search found 22 references and analyzed 12, including 9 clinical trials using sh-oligopeptide-1. The author concluded: “Clinical studies on sh-oligopeptide-1 have no scientific basis.” The review also found that the trials did not follow medical standards. The review notes that long-term risks are unknown. The author works at a Spanish clinical trials unit (Martínez-Carpio, 2023).

Abud 2026 (human pilot trial). Twenty women aged 50 to 65 were randomized, double-blind, to a recombinant EGF serum described as containing oligopeptide-1, or a human-derived EGF serum. Over 12 weeks, investigator ratings favored the recombinant serum for texture and firmness at later visits. Global wrinkle severity changed little in either group (Abud et al., 2026).

The trial had no placebo arm and was small. It tested EGF products, so it says nothing about the CosIng oligopeptide-1 peptide.

What safety data exist?

We found no Cosmetic Ingredient Review (CIR) safety assessment for oligopeptide-1 or sh-oligopeptide-1. CIR’s quick reference table, September 2020 edition, lists neither name (CIR, 2020). Searches of the CIR website and PubMed found no later report.

The same table lists Tripeptide-1 as safe as used, from a June 2014 final report. That report limits its conclusion to tripeptide-1 defined as “glycine-histidine-lysine” (CIR, 2014). The finding covers the name Tripeptide-1, not Oligopeptide-1. For sh-oligopeptide-1, the 2023 review flags unknown long-term risks.

What is oligopeptide-1’s regulatory status, and how is it used in research?

Oligopeptide-1 is a cosmetic ingredient, not an FDA-approved drug. FDA states that cosmetic products and ingredients, except color additives, “do not need FDA premarket approval” (FDA, 2025). Products meant to treat or prevent disease are drugs (FDA, 2024).

Congress enacted the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) on December 29, 2022 (FDA, 2026). It requires facility registration, product listing, serious adverse event reports within 15 business days, and safety records (FDA MoCRA page).

In research, the name mostly appears in cosmetic studies of recombinant EGF. Because some papers use oligopeptide-1 for what CosIng lists as sh-oligopeptide-1, the two are easy to mix up in the literature.

Frequently asked questions about oligopeptide-1

Is oligopeptide-1 the same as EGF?

Not under CosIng. Oligopeptide-1 is a glycine, histidine and lysine peptide. Recombinant human EGF is listed as sh-oligopeptide-1.

Is oligopeptide-1 the same as GHK?

PubChem files the name under GHK acetate. CosIng gives only a general description, so we cannot confirm an exact sequence.

Is oligopeptide-1 a peptide?

Yes. CosIng describes a short chain built from glycine, histidine and lysine.

Is oligopeptide-1 FDA-approved?

No. It is a cosmetic ingredient. US cosmetic ingredients, other than color additives, do not need FDA premarket approval.

Has CIR reviewed oligopeptide-1?

Not that we found. CIR has assessed tripeptide-1, a related name, but not oligopeptide-1 or sh-oligopeptide-1.

What to know now

  • Definition: CosIng calls oligopeptide-1 “Glycine, oligomer with histidine and lysine.”
  • Name trap: sh-oligopeptide-1 is a separate entry for recombinant EGF, up to 53 amino acids.
  • CosIng function: skin conditioning for both.
  • Evidence: PubMed records under the name concern EGF; a 2023 review found sh-oligopeptide-1 trials lacked scientific basis.
  • Safety: no CIR assessment for either name.
  • Status: cosmetic ingredient; not an FDA-approved drug.

What we’re watching

FDA’s ongoing MoCRA rollout, tracked on its MoCRA page. Any CIR review of oligopeptide-1 or sh-oligopeptide-1, which would appear on cir-safety.org. Related guides: GHK-Cu, palmitoyl tripeptide-1 and carnosine.

More for skin & connective tissue

All 23 compounds for skin & connective tissue

Sources: European Commission 2026, CosIng: OLIGOPEPTIDE-1; European Commission 2026, CosIng: SH-OLIGOPEPTIDE-1; National Center for Biotechnology Information 2026, PubChem compound summary for CID 22214678, prezatide monoacetate (Gly-His-Lys acetate); Martínez-Carpio 2023, Cutaneous and Ocular Toxicology, 42; Abud 2026, Journal of Cosmetic Dermatology, 25; National Library of Medicine 2026, PubMed search: “oligopeptide-1”[tiab]; Cosmetic Ingredient Review 2020, Quick reference table; Cosmetic Ingredient Review 2014; U.S. Food and Drug Administration 2025, FDA authority over cosmetics: How cosmetics are not FDA-approved, but are FDA-regulated; U.S. Food and Drug Administration 2024, Is it a cosmetic, a drug, or both? (Or is it soap?); U.S. Food and Drug Administration 2026, Modernization of Cosmetics Regulation Act of 2022 (MoCRA); Kozlowski 2026, How FDA is implementing landmark cosmetics legislation to positively impact public health. All 12 citations

Back to the research library

References

  1. European Commission. (2026). CosIng: OLIGOPEPTIDE-1 (substance ID 57786). Retrieved November 17, 2026, from https://ec.europa.eu/growth/tools-databases/cosing/details/57786
  2. European Commission. (2026). CosIng: SH-OLIGOPEPTIDE-1 (substance ID 87479). Retrieved November 17, 2026, from https://ec.europa.eu/growth/tools-databases/cosing/details/87479
  3. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 22214678, prezatide monoacetate (Gly-His-Lys acetate). Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/22214678
  4. Martínez-Carpio, P. A. (2023). Topical application of sh-oligopeptide-1 and clinical trials with cosmetic preparations: Risk or fraud? Cutaneous and Ocular Toxicology, 42(4), 190-197. https://doi.org/10.1080/15569527.2023.2234020
  5. Abud, B., et al. (2026). A randomized, double-blinded pilot study comparing synthetic versus human-derived topical epidermal growth factor for facial rejuvenation and psychosocial perception. Journal of Cosmetic Dermatology, 25(5), e70927. https://doi.org/10.1111/jocd.70927
  6. National Library of Medicine. (2026). PubMed search: “oligopeptide-1”[tiab] (3 results). Retrieved November 17, 2026, from https://pubmed.ncbi.nlm.nih.gov/?term=%22oligopeptide-1%22%5Btiab%5D
  7. Cosmetic Ingredient Review. (2020). Quick reference table (September 2020). Retrieved November 17, 2026, from https://www.cir-safety.org/sites/default/files/qrt-fix_0.pdf
  8. Cosmetic Ingredient Review. (2014). Safety assessment of tripeptide-1, hexapeptide-12, their metal salts and fatty acyl derivatives, and palmitoyl tetrapeptide-7 as used in cosmetics (final report, June 2014). Retrieved November 17, 2026, from https://www.cir-safety.org/sites/default/files/tripep062014final.pdf
  9. U.S. Food and Drug Administration. (2025). FDA authority over cosmetics: How cosmetics are not FDA-approved, but are FDA-regulated (content current as of 11/18/2025). Retrieved November 17, 2026, from https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated
  10. U.S. Food and Drug Administration. (2024). Is it a cosmetic, a drug, or both? (Or is it soap?) (content current as of 09/11/2024). Retrieved November 17, 2026, from https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soap
  11. U.S. Food and Drug Administration. (2026). Modernization of Cosmetics Regulation Act of 2022 (MoCRA) (content current as of 10/29/2026). Retrieved November 17, 2026, from https://www.fda.gov/cosmetics/cosmetics-laws-regulations/modernization-cosmetics-regulation-act-2022-mocra
  12. Kozlowski, S. (2026). How FDA is implementing landmark cosmetics legislation to positively impact public health (FDA Voices; content current as of 05/04/2026). U.S. Food and Drug Administration. https://www.fda.gov/news-events/fda-voices/how-fda-implementing-landmark-cosmetics-legislation-positively-impact-public-health